Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 3/20 | 0.40 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 8/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 6/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 5/20 | 0.39 |
| ▸ | MMP9 | P14780 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | MMP1 | P03956 | 1/20 | 0.37 |
| ▸ | MMP2 | P08253 | 1/20 | 0.37 |
| ▸ | MMP8 | P22894 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4651696 | 1.00 | KCNA5 (0.40) | KCNA5KCNK3CHRM1CHRM2CHRM4 | |
| SCHEMBL4651408 | 0.82 | NR1H2 (0.41) | CHRM1CHRM2CHRM4MEN1ALDH1A1 | |
| SCHEMBL4652641 | 0.82 | EPHX2 (0.38) | CHRM1CHRM2CHRM4MMP9MEN1 | |
| SCHEMBL5121326 | 0.82 | NR1H2 (0.41) | CHRM1CHRM2CHRM4MEN1ALDH1A1 | |
| SCHEMBL4652861 | 0.82 | EPHX2 (0.38) | CHRM1CHRM2CHRM4MMP9MEN1 | |
| SCHEMBL2113831 | 0.82 | NR1H2 (0.41) | CHRM1CHRM2CHRM4MEN1ALDH1A1 | |
| SCHEMBL4651411 | 0.82 | NR1H2 (0.41) | CHRM1CHRM2CHRM4MEN1ALDH1A1 | |
| SCHEMBL2113457 | 0.82 | EPHX2 (0.38) | CHRM1CHRM2CHRM4MMP9MEN1 | |
| SCHEMBL4652854 | 0.81 | KDM4E (0.44) | CHRM1CHRM2CHRM4MMP9MEN1 | |
| SCHEMBL4652856 | 0.81 | KDM4E (0.44) | CHRM1CHRM2CHRM4MMP9MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1644320-B1 | INDANE DERIVATES AS MUSCARINIC RECEPTOR AGONISTS | LILLY CO ELI (US) | 2008-01-16 | — | — | EP | disclosed |
| US-7265246-B2 | Indane derivates as muscarinic receptor agonists | ELI LILLY AND COMPANY (US) | 2007-09-04 | — | — | US | disclosed |
| US-20070060587-A1 | Indane derivates as muscarinic receptor agonists | ELI LILLY AND COMPANY (US) | 2007-03-15 | — | — | US | disclosed |
| EP-1644320-A1 | INDANE DERIVATES AS MUSCARINIC RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2006-04-12 | — | — | EP | disclosed |
| WO-2005009941-A1 | INDANE DERIVATES AS MUSCARINIC RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2005-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060587-A1 | Indane derivates as muscarinic receptor agonists | CHRM1, CHRM3, CHRM2 | KCNA5 207/4885KCNK3 571/4885CHRM1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.